Advertisements

Pivotal Therapeutics Inc. (PVO:CNX) Stock Quote

Detailed Quote for Pivotal Therapeutics Inc. (PVO:CNX)
$ 0.05 0.00 (0.00%) Volume: 0 3:05 PM EST Feb 4, 2016
Today 5d 1m 3m 1y more
Last Price
0.05
Change $
Change %
Tick
  
Bid
0.03
Bid Size
25,000
Ask
0.05
Ask Size
21,000
Open
N/A
High
N/A
Low
N/A
Prev Close
0.05
Last Trade
02/04/16
Volume
0
52 Wk Hi
0.15
52 Wk Low
0.03
Market Cap
4.83m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
96,566,669
EPS (TTM)
-0.04
PE Ratio
N/A
Exchange
CSE
News and Media for Pivotal Therapeutics Inc. (PVO:CNX)
Sector News | Topic News
News for Pivotal Therapeutics Inc. (PVO:CNX)
Tue, Feb 02, 2016
5:36 PM Pivotal Therapeutics Announces Issuance of US Patent 9,248,138 for the Stabilization of Vulnerable Plaque Utilizing a Combination of Statin and Omega 3 Fatty Acids - TheNewsWire
Mon, Jan 04, 2016
9:28 PM Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes - TheNewsWire
Mon, Nov 30, 2015
12:43 PM Pivotal Therapeutics Announces Third Quarter Financial Results and Executes Distribution Agreement - TheNewsWire
Fri, Nov 27, 2015
5:55 PM Pivotal Therapeutics Closes First Tranche of Equity Financing - TheNewsWire
Wed, Nov 25, 2015
5:45 PM BeneFishial(TM) Pet Formulation Approved For Sale - The First in Pivotal's Animal Health and Nutrition Line - TheNewsWire
Fri, Nov 06, 2015
3:12 PM Pivotal Announces Publication Evaluating 171 Over-the-Counter (OTC) Omega-3 Nutritional Supplements - 50% of the OTC Products Failed at Least one of the Oxidative Safety Limits - TheNewsWire
Thu, Nov 05, 2015
5:04 PM Pivotal Therapeutics Announces Proposed Equity Financing - TheNewsWire
Thu, Oct 08, 2015
3:36 PM Pivotal Receives Notice of Allowance for U.S. Application 14/594,095 for the Stabilization of Vulnerable Plaque Utilizing a Combination of Statin and PVT-100 - TheNewsWire
Mon, Sep 28, 2015
11:35 AM Pivotal Therapeutics Announces Payment Of Interest On Outstanding Convertible Notes - TheNewsWire
Tue, Sep 22, 2015
7:00 AM Pivotal Therapeutics Announces Issuance of U.S. Patent 9,119,826 for a Kit that Includes Vascazen(tm) and an Omega-3 Fatty Acid Diagnostic Asssay for the Dietary Management of Cardiovascular Patients Deficient in Omega-3 - TheNewsWire
Fri, Aug 28, 2015
9:52 PM Pivotal Therapeutics Announces Second Quarter Financial Results - TheNewsWire
Mon, Jun 29, 2015
8:43 PM Pivotal Therapeutics Announces Proposed Private Placement - TheNewsWire
Thu, Jun 18, 2015
5:53 PM Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes - Canada Newswire
Thu, Jun 04, 2015
2:25 PM First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100 - Canada Newswire
Mon, Jun 01, 2015
9:19 PM Pivotal Therapeutics Announces First Quarter Financial Results - Canada Newswire
Mon, May 11, 2015
3:17 PM Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel - Canada Newswire
Thu, Apr 30, 2015
9:20 PM Pivotal Therapeutics Announces 2014 Financial Results - Canada Newswire
Mon, Apr 27, 2015
12:48 PM Pivotal receives Health Canada approval to expand the indication of OMAZEN\u00AE to include products with claims to maintain and support cardiovascular health and normal triglyceride levels - Canada Newswire
Wed, Apr 15, 2015
9:10 AM Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial(TM) line of products in Korea - Canada Newswire
Tue, Apr 07, 2015
11:00 AM Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg Laureate of EUR 30,000 French Interregional Clinical Research and Innovation Award For Investigating the Therapeutic Value of Its Novel VASCAZEN\u00AE Formulation in France - Canada Newswire
More News for PVO:CNX >>

Tags for Pivotal Therapeutics Inc.

Research stocks or mutual funds related to Pivotal Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to PVO:CNX. The keywords below have been associated to PVO:CNX by either user submission or electronic means.